{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T18:48:18Z","timestamp":1775846898534,"version":"3.50.1"},"reference-count":37,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"unspecified","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Cancer Innovative Research Program of Sun Yat-sen University Cancer Center","award":["CIRP-SYSUCC-0022"],"award-info":[{"award-number":["CIRP-SYSUCC-0022"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270198"],"award-info":[{"award-number":["82270198"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470237"],"award-info":[{"award-number":["82470237"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82500236"],"award-info":[{"award-number":["82500236"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82570232"],"award-info":[{"award-number":["82570232"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U24A20679"],"award-info":[{"award-number":["U24A20679"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,3,30]]},"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Immune checkpoint inhibitors achieve high response rates in relapsed or refractory (r\/r) classical Hodgkin lymphoma (cHL), but few treatment options are available for patients who experience failure after PD-1\/PD-L1 blockade. T cell immunoglobulin and mucin-domain containing-3, a key mediator of immune escape from PD-1\/PD-L1 inhibition, is targeted by TQB2618, a humanized IgG\n                      <jats:sub>4<\/jats:sub>\n                      monoclonal antibody. This phase Ib study aimed to evaluate the safety and efficacy of TQB2618 in combination with the anti-PD-1 antibody penpulimab in patients with r\/r cHL.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This multicenter phase 1b study was conducted from June 2022 to September 2024 at 12 sites in China (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05400876\">NCT05400876<\/jats:ext-link>\n                      ). The study included a dose-escalation phase in which patients with r\/r lymphoma received TQB2618 (600 or 1200\u2009mg, every 3 weeks, Q3W) plus penpulimab (200\u2009mg, Q3W) to evaluate dose-limiting toxicities and determine the recommended phase II dose (RP2D). The subsequent dose-expansion phase enrolled patients with r\/r cHL previously treated with PD-1\/PD-L1 inhibitors to assess the objective response rate (ORR).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>10 patients with r\/r lymphoma were enrolled in the dose-escalation phase, and TQB2618 (600\u2009mg, Q3W) plus penpulimab (200\u2009mg, Q3W) was selected as the RP2D. In the dose-expansion phase, 18 additional patients with r\/r cHL previously treated with PD-1\/PD-L1 inhibitors were enrolled. Among the total 21\u2009r\/r cHL patients, the median age was 32 years (range, 22\u201365), and 12 (57%) were male. The ORR was 52%, including 1 complete response and 10 partial responses. Treatment-related adverse events (TRAEs) occurred in 18 patients (86%), with grade \u22653 TRAEs in 5 (24%). The most common TRAEs (\u226520%) were platelet count decreased (24%), anemia (24%), and aspartate aminotransferase increased (24%). As of the data cut-off in December 2024, the median follow-up was 14.1 months, the median duration of response and the median overall survival had not yet been reached.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>TQB2618 in combination with penpulimab was well tolerated and demonstrated promising efficacy in patients with cHL who had failed prior anti-PD-1\/PD-L1 therapy, supporting its potential as a therapeutic option for this difficult-to-treat population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05400876\">NCT05400876<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2026-014968","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:50:14Z","timestamp":1775843414000},"page":"e014968","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Anti-TIM-3 antibody TQB2618 in combination with penpulimab in relapsed or refractory classic Hodgkin lymphoma previously treated with PD-1\/PD-L1 therapy: a multicenter, open-label, single-arm, phase Ib clinical trial"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct05400876","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05400876","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Huangming","family":"Hong","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, Sichuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4755-6711","authenticated-orcid":false,"given":"Zegeng","family":"Chen","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Hematology, Gansu Provincial Cancer Hospital, Lanzhou, Gansu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingyuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanghai Tongji Hospital, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Tao","sequence":"additional","affiliation":[{"name":"Fudan University Shanghai Cancer Center, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"He","family":"Huang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binghua","family":"Wang","sequence":"additional","affiliation":[{"name":"Weihai Municipal Hospital, Weihai, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wuping","family":"Li","sequence":"additional","affiliation":[{"name":"Jiangxi Cancer Hospital, Nanchang, Jiangxi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Wu","sequence":"additional","affiliation":[{"name":"Fujian Cancer Hospital, Fuzhou, Fujian, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Wei","sequence":"additional","affiliation":[{"name":"Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Su","sequence":"additional","affiliation":[{"name":"Shanxi Cancer Hospital, Taiyuan, Shanxi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihua","family":"Zhang","sequence":"additional","affiliation":[{"name":"Chengde Medical University Affiliated Hospital, Chengde, Hebei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingxing","family":"Zhong","sequence":"additional","affiliation":[{"name":"Ganzhou People\u2019s Hospital, Ganzhou, Jiangxi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huaqing","family":"Wang","sequence":"additional","affiliation":[{"name":"Tianjin City People\u2019s Hospital, Tianjin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cong","family":"Wang","sequence":"additional","affiliation":[{"name":"Wuwei Cancer Hospital of Gansu Province, Lanzhou, Gansu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Zhou","sequence":"additional","affiliation":[{"name":"Hunan Cancer Hospital, Changsha, Hunan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jishi","family":"Wang","sequence":"additional","affiliation":[{"name":"The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Dong","sequence":"additional","affiliation":[{"name":"The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tongyu","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, Sichuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"2026041010500808000_14.4.e014968.1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41572-020-0189-6","article-title":"Hodgkin lymphoma","volume":"6","author":"Connors","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2026041010500808000_14.4.e014968.2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2016.05.007"},{"key":"2026041010500808000_14.4.e014968.3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.4482"},{"key":"2026041010500808000_14.4.e014968.4","first-page":"2727","article-title":"Improved outcomes for relapsed\/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents","volume":"141","author":"Spinner","year":"2023","journal-title":"Blood"},{"key":"2026041010500808000_14.4.e014968.5","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000324"},{"key":"2026041010500808000_14.4.e014968.6","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1200\/JCO-25-00204","article-title":"Nivolumab-AVD versus brentuximab vedotin-AVD in older patients with advanced-stage classical Hodgkin lymphoma enrolled on S1826","volume":"43","author":"Rutherford","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026041010500808000_14.4.e014968.7","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1200\/JCO-24-01278","article-title":"Phase II trial of nivolumab plus doxorubicin, vinblastine, dacarbazine as frontline therapy in older adults with Hodgkin lymphoma","volume":"43","author":"Torka","year":"2025","journal-title":"JCO"},{"key":"2026041010500808000_14.4.e014968.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2405888"},{"key":"2026041010500808000_14.4.e014968.9","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41392-023-01600-7","article-title":"Long-term survival benefit of anti-PD-1 therapy in patients with relapsed or refractory classical Hodgkin lymphoma","volume":"8","author":"Liu","year":"2023","journal-title":"Sig Transduct Target Ther"},{"key":"2026041010500808000_14.4.e014968.10","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1182\/blood.2022019386","article-title":"Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed\/refractory classical Hodgkin lymphoma","volume":"142","author":"Armand","year":"2023","journal-title":"Blood"},{"key":"2026041010500808000_14.4.e014968.11","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-025-01257-1","article-title":"Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers","volume":"15","author":"Voorhees","year":"2025","journal-title":"Blood Cancer J"},{"key":"2026041010500808000_14.4.e014968.12","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/jamaoncol.2022.7975","article-title":"Pembrolizumab added to ifosfamide, carboplatin, and etoposide chemotherapy for relapsed or refractory classical Hodgkin lymphoma: a multi-institutional phase 2 investigator-initiated nonrandomized clinical trial","volume":"9","author":"Bryan","year":"2023","journal-title":"JAMA Oncol"},{"key":"2026041010500808000_14.4.e014968.13","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/S2352-3026(22)00318-0","article-title":"Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial","volume":"10","author":"Herrera","year":"2023","journal-title":"Lancet Haematol"},{"key":"2026041010500808000_14.4.e014968.14","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.21.01056","article-title":"Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma","volume":"39","author":"Moskowitz","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026041010500808000_14.4.e014968.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2024.01.010"},{"key":"2026041010500808000_14.4.e014968.16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41586-021-03626-9","article-title":"TIM-3 restrains anti-tumour immunity by regulating inflammasome activation","volume":"595","author":"Dixon","year":"2021","journal-title":"Nature New Biol"},{"key":"2026041010500808000_14.4.e014968.17","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15061697","article-title":"T cell immunoglobulin and mucin domain 3 (TIM-3) in cutaneous melanoma: a narrative review","volume":"15","author":"Cazzato","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026041010500808000_14.4.e014968.18","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-023-01499-1","article-title":"Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy","volume":"16","author":"Cai","year":"2023","journal-title":"J Hematol Oncol"},{"key":"2026041010500808000_14.4.e014968.19","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat Commun"},{"key":"2026041010500808000_14.4.e014968.20","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-020-00212-5","article-title":"Resistance to PD-1\/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives","volume":"8","author":"Sun","year":"2020","journal-title":"Biomark Res"},{"key":"2026041010500808000_14.4.e014968.21","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1158\/1078-0432.CCR-25-0884","article-title":"Combined targeting of PD-1 and TIM-3 in patients with locally advanced or metastatic melanoma: AMBER cohorts 1c, 1e, and 2A","volume":"31","author":"Davar","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2026041010500808000_14.4.e014968.22","doi-asserted-by":"crossref","DOI":"10.1186\/s43556-025-00267-6","article-title":"TIM-3 teams up with PD-1 in cancer immunotherapy: mechanisms and perspectives","volume":"6","author":"Yan","year":"2025","journal-title":"Mol Biomed"},{"key":"2026041010500808000_14.4.e014968.23","doi-asserted-by":"crossref","first-page":"6031","DOI":"10.1200\/JCO.2025.43.16_suppl.6031","article-title":"Combination of Tim-3 blockade TQB2618 with penpulimab and chemotherapy in the first-line treatment of recurrent\/metastatic nasopharyngeal carcinoma (R\/M NPC): A multicenter, single-arm, two-cohort, phase 2 study","volume":"43","author":"Xu","year":"2025","journal-title":"JCO"},{"key":"2026041010500808000_14.4.e014968.24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4746"},{"key":"2026041010500808000_14.4.e014968.25","doi-asserted-by":"crossref","unstructured":"Gutierrez ME , Tang S-C , Powderly JD , et al . First-in-human phase I open-label study of the anti\u2013TIM-3 monoclonal antibody INCAGN02390 in patients with select advanced or metastatic solid tumors. Oncologist 2025;30. doi:10.1093\/oncolo\/oyaf144","DOI":"10.1093\/oncolo\/oyaf144"},{"key":"2026041010500808000_14.4.e014968.26","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1158\/1078-0432.CCR-25-0806","article-title":"Combined targeting of PD-1 and TIM-3 in patients with locally advanced or metastatic non-small cell lung cancer: AMBER part 2B","volume":"31","author":"Davar","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2026041010500808000_14.4.e014968.27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-781989"},{"key":"2026041010500808000_14.4.e014968.28","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.clml.2020.11.009","article-title":"Expression of the immune checkpoint regulators LAG-3 and TIM-3 in classical Hodgkin lymphoma","volume":"21","author":"El Halabi","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2026041010500808000_14.4.e014968.29","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1006-1"},{"key":"2026041010500808000_14.4.e014968.30","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1519082","article-title":"Immune-related adverse events with PD-1\/PD-L1 inhibitors: insights from a real-world cohort of 2523 patients","volume":"16","author":"Yan","year":"2025","journal-title":"Front Pharmacol"},{"key":"2026041010500808000_14.4.e014968.31","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10040790","article-title":"Review of immune-related adverse events (irAEs) in non-small-cell lung cancer (NSCLC)-their incidence, management, multiorgan irAEs, and rechallenge","volume":"10","author":"Vaddepally","year":"2022","journal-title":"Biomedicines"},{"key":"2026041010500808000_14.4.e014968.32","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000971168.59900.67","article-title":"P1068: updated results from an open-label phase 1\/2 study of favezelimab in combination with pembrolizumab in patients with relapsed or refractory classical Hodgkin lymphoma after anti\u2013PD-1 treatment","volume":"7","author":"Timmerman","year":"2023","journal-title":"HemaSphere"},{"key":"2026041010500808000_14.4.e014968.33","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1182\/blood.2023020485","article-title":"Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade","volume":"142","author":"Mei","year":"2023","journal-title":"Blood"},{"key":"2026041010500808000_14.4.e014968.34","doi-asserted-by":"crossref","DOI":"10.1126\/science.ade8520","article-title":"JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma","volume":"384","author":"Zak","year":"2024","journal-title":"Science"},{"key":"2026041010500808000_14.4.e014968.35","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0201"},{"key":"2026041010500808000_14.4.e014968.36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1604958"},{"key":"2026041010500808000_14.4.e014968.37","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54512-7","article-title":"Cancer-specific innate and adaptive immune rewiring drives resistance to PD-1 blockade in classic Hodgkin lymphoma","volume":"15","author":"Paczkowska","year":"2024","journal-title":"Nat Commun"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2026-014968","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:50:19Z","timestamp":1775843419000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2026-014968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":37,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,10]]},"published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1136\/jitc-2026-014968"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2026-014968","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]}}}